Member Info for Prion25

I think Dr Boulevard is hedging his bets for Ivermectin in a quest for a cheap drug even if 600 mcg is only marginally beneficial this will not deter him in his belief in ivermectin Curious behaviour lol

https://www.nature.com/articles/s41586-022-04569-5
Moving from investigations of LC on the lungs to the brain This article provides an insight into interesting research and may explain why we are having to wait so long patiently for our LC data ATB

https://www.healthcare.scientexconference.com/speakers/Stacey-J-Adam
Good profile on Stacey ‘s work with FNIH and her endeavours to elucidate safe and effective therapeutics

I think a peer reviewed conference report will not not the same as an "in house" rigorous Lancet publication imo

I am managing my expectations yet again .All we can expect as positive news is another trial and a peer review publication Just reading this article on long COVID on a small study by NIAID in long COVID patients "Plasma and blood samples from a subgroup of participants were analyzed by scientists for levels of various inflammatory biomarkers, as well as markers of lymphocyte activation. These studies did not find evidence of abnormal activation of the immune system in people with long COVID. "
Its disappointing they did not find evidence of type 1 autoantibodies in these patients
Now Activ 2 blood samples were taken but not in P3 We still awaiting for the Activ 2 data and P3 long COVID investigations to offer a glimmer of hope
https://www-novarnish.niaid.nih.gov/news-events/niaid-study-focuses-long-covid-symptoms

Retired not resigned ! read the RNS
Graeme Lewis, Chief Financial Officer, has today informed the Company that he wishes to retire. In order to ensure an orderly handover to his successor, Graeme has agreed to stay with the Company until 30 April 2023. The Company has commenced the process of recruiting a successor and will update the market in due course.

Synairgen’s SG018 trial is a randomised placebo-controlled study being conducted in approximately 20 countries enrolling a total of 610 COVID-19 patients who require supplemental oxygen. After reporting the results for the primary and key secondary endpoints of the study, enrolled patients will continue to be assessed for long-COVID-19 symptoms.
https://www.southampton.ac.uk/news/2021/01/synairgen-phase-iii-trial.page

I see they do supply components for the military ‘s defence systems

Good sound bite from Lemos Will the chips /wafers find their way in to smart military weapons to use against the unethical despot in the Kremlin ? Out of interest does anybody know ? Thanks

Interesting subgroup to be Investigated- Operation Time Warp

https://www.msn.com/en-gb/health/mindandbody/neanderthal-gene-probably-caused-up-to-a-million-covid-deaths/ar-AAYgLF3?bk=1&ocid=msedgntp&cvid=8bfcf7ad49144d3bb93a0f9878a12349

AstraZenica in talks over Covid drug Evusheld for vulnerable and immunocompromised UK patients Saturdays Daily Telegraph

https://www.investegate.co.uk/clinigen-group-plc/rns/clinigen-signs-map-agreement-with-synairgen/202009290700083695A/
Not sure if this MAP is still applicable but it gives a tel number where Health Professionals
in the EU can obtain drug ATB

https://bvalive.vetshow.com/exhibitors/avacta-animal-health?&azletterfield=title&sortby=title%20asc&azLetterField=title&searchgroup=libraryentry-exhibitors
Avacta Animal health ?

Sounded optimistic to me Having identified this respondent group to our drug which may included all viruses and regardless of age ? Seem like it could be a perfect for treatment for a clinician to save lives in hospitalised patients RM probably could not mention any commercial sensitive stuff ?

Scinv
Good to hear from you again. Data, dredging , p hacking and cherry picking sounds the company is desperately skewing the results for what reason .?They acknowledge the primary end points have failed against much improved SOC and found a definite benefit of the treatment to save lives in a very vulnerable group, this is indeed is valuable data .I never doubted the integrity of the company and I am sure the peer review will reflect this

Excellent news 70 % reduction in serious disease and death in the most vulnerable patients on oxygen and a TEAE overall appears safer than the top line SOC placebo ! Shame they didn't take blood samples to top up the post hoc analysis and no mention of long Covid or is there more to come ? GLA

Thanks Manifesto for the link
Just bought Deborah a drink .Money well spent on a worthy cause and an inspirational lady rather than this enigma of a share

Manifesto
You are correct it's non regulatory as stated in this morning's RNs/NR by Reach
"This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. "

They also included 120 patients from the Home Trial in the presentation as well as P2

BBC report on unusual increases in hepatitis in children in US and Europe states in not a result of C19 vaccines. If vaccines suppress interferon I wonder if there is a link or whether it just the affect of suppression induced by contact with the virus or is it what we already understand is the presence of auto antibodies etc .All this valuable epidemiological information has sadly gone astray with SNG not taking blood samples : (
https://www.bbc.co.uk/news/world-europe-61157909